Ipamorelin: Protease Resistance Without an Anchor

The short version

Ipamorelin is a very small lab-made peptide — five building blocks long. It works on a different pituitary switch from CJC-1295 and tesamorelin: the receptor that natural ghrelin uses. Flipping it releases a burst of growth hormone.

Three of its five building blocks are unusual forms that blood enzymes struggle to cut. That is its only defence. Nothing attaches it to a carrier protein, and no fatty chain slows its exit.

So it clears fast. In healthy male volunteers given it by drip, half of it was gone from the blood in about 2 hours ^[11]. The growth-hormone response was a single burst peaking around 40 minutes after the dose, not a plateau ^[11].

That number came from an intravenous drip, which matters: a figure measured one way does not transfer to another route without being measured again. Ipamorelin has never been approved as a medicine, and its only completed trial in people missed its main goal ^[10].

What it is

Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. Position 1 is alpha-aminoisobutyric acid, a non-standard residue; positions 3 and 4 are D-2-naphthylalanine and D-phenylalanine, D-amino acids that proteases handle poorly. It was derived from GHRP-1 by removing the central Ala-Trp dipeptide, and it is also catalogued as NNC 26-0161.

D-amino acid substitution is the cheapest half-life extension strategy in peptide chemistry. Proteases evolved to cleave L-amino acid chains; substituting the mirror-image residue at a cleavage site makes the bond a poor substrate. It costs nothing in molecular weight and requires no conjugation step.

It is also the weakest of the strategies represented on this desk. Resisting enzymatic degradation does not stop glomerular filtration, and a molecule this small is filtered freely. CJC-1295 and semaglutide both add a second layer — albumin binding, covalent in one case and reversible in the other — precisely because protease resistance alone leaves renal clearance untouched. Ipamorelin has no second layer, which makes it the useful control in a set of four.

How it works

Ipamorelin is a selective agonist of the ghrelin receptor, GHS-R1a, on pituitary somatotrophs. Activating it triggers a pulse of growth-hormone release by a mechanism distinct from and complementary to that of GHRH — which is the pharmacological rationale behind pairing it with GHRH analogues such as CJC-1295, though no trial of that combination appears in this reference set.

Its signature property is selectivity. Unlike the earlier growth-hormone-releasing peptides GHRP-6 and GHRP-2, it does not meaningfully raise ACTH, cortisol or prolactin, even well above the dose producing half its maximal growth-hormone effect. That comparative selectivity is a documented feature of the compound; the founding characterisation supporting it sits outside this digest's reference set and so carries no citation number here.

GHS-R1a is not confined to the pituitary. It is expressed on enteric and vagal neurons governing gastric motility, on pancreatic islet cells, and in hypothalamic appetite circuitry. A receptor's address predicts its side-effect profile better than any marketing claim does, and this receptor has several addresses.

What the research shows

The human pharmacokinetics are the most precisely characterised on this desk, and they come from one study.

Population PK/PD modelling in healthy male volunteers — eight subjects per dose level, five 15-minute intravenous infusions spanning 4.21 to 140.45 nanomoles per kilogram — showed dose-proportional kinetics with a terminal half-life of approximately 2 hours, clearance of 0.078 litres per hour per kilogram, and a steady-state volume of distribution of 0.22 litres per kilogram. The growth-hormone response peaked at about 0.67 hours, roughly 40 minutes after dosing, as a single discrete pulse ^[11]. Those are human figures, measured intravenously.

The volume of distribution is worth pausing on. At 0.22 litres per kilogram ^[11] it is close to extracellular fluid volume, meaning the peptide stays largely in the water compartment rather than distributing into tissue — the expected behaviour for a small, hydrophilic, unbound molecule, and the opposite of what albumin conjugation produces.

The clinical record is thin and negative. The only published Phase 2 randomised controlled trial enrolled 114 adults undergoing bowel resection, giving 0.03 milligrams per kilogram intravenously twice daily for up to seven days. It missed its primary endpoint: median time to first tolerated meal was 25.3 hours with ipamorelin against 32.6 hours with placebo, p=0.15. Treatment-emergent adverse events occurred in 87.5 per cent of the ipamorelin arm and 94.8 per cent of the placebo arm ^[10].

The animal work carries most of the remaining evidence, and the species are not interchangeable with each other or with people. In adult female Sprague-Dawley rats, subcutaneous ipamorelin at 18, 90 and 450 micrograms per day divided three times daily for 15 days raised the longitudinal bone growth rate from 42 micrometres per day on vehicle to 44, 50 and 52 micrometres per day respectively, with no change in total IGF-1, IGF-binding proteins or bone turnover markers ^[12]. In a 2024 ferret study — the most recent published in-vivo work on the compound — intraperitoneal ipamorelin at 1 to 3 milligrams per kilogram reduced cisplatin-induced body-weight loss by about 24 per cent on the last day of the delayed phase, 48 to 72 hours, but had no anti-emetic effect in either the acute or delayed phase, in contrast to intracerebroventricular anamorelin, which cut acute emesis by 60 per cent ^[8].

Reported effects, cautions and safety

The reports below come from peptide-user forums and clinic summaries of client feedback. They are anecdotal, not clinical evidence, and no doses are attached to them.

Deeper and more restorative sleep and vivid dreams in the early weeks are frequently reported, as is faster physical recovery with less post-training soreness. A gradual shift toward leaner body composition over weeks to months is reported occasionally.

On the adverse side, facial flushing and a head-rush shortly after injection are frequently reported. Tingling or numbness in the hands and feet, mild water retention, increased hunger in the hours after injection, early fatigue or dizziness, injection-site irritation, and a diminishing response over months of continuous use are all reported occasionally. The appetite reports are consistent with the receptor: GHS-R1a is the ghrelin receptor, and ghrelin is an appetite hormone.

The documented cautions are these. Long-term human safety is uncharacterised: the only controlled human data are the single Phase 2 trial over a short perioperative window ^[10] and the acute single-dose PK/PD study ^[11], with no Phase 3 trial and no approved indication anywhere. A 28-day integrated preclinical safety study of a different GHS-R1a agonist, GSK894281, found dose-dependent myocardial degeneration and necrosis in rats, detectable by histopathology and electron microscopy and accompanied by elevated serum heart-type fatty-acid-binding protein at the highest doses, while cardiac troponin was not elevated — a class-level cardiovascular signal in rats, not a finding about ipamorelin itself, but the reason chronic systemic dosing in this class attracts scrutiny ^[9].

Four further cautions in the record rest on sources outside this digest's reference set and so carry no citation number: the mechanistic concern around active or recent malignancy and proliferative conditions, since growth hormone drives hepatic IGF-1 production and IGF-1 is a well-characterised mitogen; reduced peripheral insulin sensitivity and raised fasting glucose from sustained growth-hormone elevation, alongside a GH-independent insulinotropic action on pancreatic islet tissue; central appetite stimulation and adiposity effects observed in mice; and the comparative selectivity note about minimal cortisol and prolactin elevation. Ipamorelin is also prohibited in sport at all times under WADA category S2, and most material sold is research-grade of variable purity from unregulated suppliers.

Where it sits on the kinetics map

Ipamorelin marks the short end of this desk, and it is the most instructive compound here for exactly that reason.

Its terminal half-life of about 2 hours in healthy male volunteers ^[11] sits against CJC-1295's estimated 5.8 to 8.1 days in healthy adults ^[4] — a difference of roughly two orders of magnitude between two compounds that both act on the pituitary to release growth hormone. The receptor is not what separates them. The chemistry is. One carries a covalent albumin conjugate; the other carries D-amino acids and nothing else.

There is a second lesson in the number, and it is about method rather than molecules. The 2-hour figure was measured after intravenous infusion ^[11]. Subcutaneous injection introduces an absorption step that can dominate the observed disappearance curve entirely, and a compound can look longer-lived by that route without any change to how fast the body eliminates it. Quoting the intravenous number for a subcutaneous injection is a category error, and it is a common one in this subject.

The pharmacodynamics are cleaner than the pharmacokinetics suggest. A single discrete growth-hormone pulse peaking at about 40 minutes ^[11] is the profile of a molecule that arrives, acts and leaves — the opposite of the sustained plateau CJC-1295 produces ^[4], and a genuinely different experiment on the same axis.